Guidance
Update information
Major changes since publication
May 2021: We reinstated and amended recommendations in line with updated MHRA safety advice on the risk of serious liver injury with ulipristal acetate (Esmya).
March 2020: In response to updated MHRA advice on the use of ulipristal acetate (Esmya), we amended or withdrew recommendations referring to ulipristal acetate.
March 2018: We added new recommendations on investigations for heavy menstrual bleeding (HMB) and management. These recommendations are marked as [2018].
Some changes were made to recommendation wording without an evidence review. These recommendations are marked as [2007, amended 2018]. These changes were mainly for ease of reading and consistency, or to reflect current practice or drug safety advice.
Minor changes since publication
December 2024: We added links to relevant technology appraisal guidance in the section on management of HMB.
October 2021: We added a link to NICE's shared decision making guideline in recommendation 1.4.1.
ISBN: 978-1-4731-2777-7